Gilead: Needham raises target price to $200 from $170
GILD•Needham raised its target price for Gilead to $200 from $170.
Related News
Azenta announces investments to advance GENEWIZ gene synthesis capabilities
AZTA•
Stereotaxis partners with Canon Medical on robotic electrophysiology systems
STXS•
Organon declares quarterly dividend of $0.02 per share
OGN•
MDA Space secures contract worth over $100 million to supply Thales Alenia Space with satellite antennas
MDA•
Profound Medical partners with Cook Medical to expand US TULSA-PRO sales
PROF•